Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma-Reference-Cited by-同舟云学术

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma

Published:2017-04-06 Issue:14 Volume:376 Page:1311-1320
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Attal Michel,Lauwers-Cances Valerie,Hulin Cyrille,Leleu Xavier,Caillot Denis,Escoffre Martine,Arnulf Bertrand,Macro Margaret,Belhadj Karim,Garderet Laurent,Roussel Murielle,Payen Catherine,Mathiot Claire,Fermand Jean P.,Meuleman Nathalie,Rollet Sandrine,Maglio Michelle E.,Zeytoonjian Andrea A.,Weller Edie A.,Munshi Nikhil,Anderson Kenneth C.,Richardson Paul G.,Facon Thierry,Avet-Loiseau Hervé,Harousseau Jean-Luc,Moreau Philippe

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa1611750

Cited by 949 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Modest survival benefits of autologous stem cell transplantation in multiple myeloma with renal impairment: a critical appraisal of the pre-antibody era;Clinical and Experimental Medicine;2024-09-09

2. Bortezomib, lenalidomide, and dexamethasone versus bortezomib, doxorubicin, and dexamethasone in newly diagnosed multiple myeloma;BMC Cancer;2024-09-09

3. Induction prior to autologous haematopoietic cell transplantation in multiple myeloma;British Journal of Haematology;2024-09-09

4. Assessment of chemotherapy-related adverse drug reactions among multiple myeloma patients at Kenyatta national hospital;Journal of Oncology Pharmacy Practice;2024-09-05

5. Tandem Autologous Stem Cell Transplantation Does Not Benefit High-Risk Myeloma Patients in the Maintenance Era: Real-World Results from The Canadian Myeloma Research Group Database;Transplantation and Cellular Therapy;2024-09